BioSpace News Archive

Merck, known as MSD outside the United States and Canada, announced that the pivotal Phase 3 RECARBRIO™ RESTORE-IMI 2 trial met its primary endpoint.

SmartPharm Therapeutics announced that José Trevejo, MD, PhD, President and Chief Executive Officer, will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7 at 8:00 a.m. ET in New York City.

Novigenix SA announced promising data from a study of a new Immuno-Transcriptomic signature for early detection of colorectal cancer (CRC) in blood.

Sept. 30, 2019 07:00 UTC Tumor regressions and partial responses observed in subjects with ovarian, non-small cell lung and bladder cancer Treatment well-tolerated, with no related Grade 3-4 or immune-related adverse events DARTMOUTH, Nova Scotia--( BUSINESS WIRE )-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today presented preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Mer

Octapharma announced that the European Medicines Agency has authorised an updated Summary of Product Characteristics for Nuwiq® that includes information on personalised prophylaxis in patients with haemophilia A.

QUANTIC NANOTECH announced the opening of free treatment sign-up registration for a new medical pre-launch pilot trial series for patients in selected hospitals in Madrid.

Two posters were presented during the European Society for Medical Oncology (ESMO) Congress 2019 on its RM-1929 photoimmunotherapy (PIT) treatment in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)

WebMD Health Corp., an Internet Brands company and the leader in health information services for consumers, physicians, and other healthcare professionals, announced that it has entered into an agreement to acquire Aptus Health.

Final results from Phase 1 study of MTL-CEBPA in advanced liver cancer patients demonstrate clinical activity and attractive safety profile

Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published in Stroke entitled “Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.”